Johnson & Johnson (JNJ)

173.29
2.20 1.30
NYSE
Prev Close 175.50
Open 174.72
Day Low/High 172.69 / 174.80
52 Wk Low/High 155.72 / 186.69
Volume 3.62M
Exchange NYSE
Shares Outstanding 2631.40B
Market Cap 470.55B
P/E Ratio 28.74
Div & Yield N.A. (N.A)

Latest News

JNJ Covered

I covered for a loss on the opening.

J&J Rental

I have taken out a short rental in Johnson & Johnson at $177.

Recession Blame, Bullard Speaks, Real Yields, Mortgage Rates, Trading Lockheed

Recession Blame, Bullard Speaks, Real Yields, Mortgage Rates, Trading Lockheed

It was what the St. Louis Fed President said regarding short-term rate targets that left the deepest impression.

More Group Stink Appears

* Stay away from the herd and the consensus in 2022   Everyone's favorite stock, Johnson & Johnson , beats but lowers sales guidance for the year.   I expect the shares to sink today.   But, the bulls will say, in the long run it will be a great inv...

Fed, Interest Rates, Earnings, Markets, China's Economy, Domestic Economics

Fed, Interest Rates, Earnings, Markets, China's Economy, Domestic Economics

Place a percentage on the likelihood of recession? It sounds more like someone trying harder to not get it wrong than trying to get it right.

Blue Monday, Technical Damage, Death Cross, FOMC, China, Raskin, Lockheed Martin

Blue Monday, Technical Damage, Death Cross, FOMC, China, Raskin, Lockheed Martin

The Nasdaq Composite suffered a 'death cross' back in mid-February and what happened after that is now clear to see.

Is it Time to Believe in a Value Rotation?

Is it Time to Believe in a Value Rotation?

Questions about the staying power of the present market turn are crucial for portfolio positioning.

Johnson & Johnson May Shed Some Tears in This Bear Market Decline

Johnson & Johnson May Shed Some Tears in This Bear Market Decline

JNJ has been in a longer-term uptrend but that may not be enough to keep the rally going.

The Most (Mr.) Wonderful Time of the Year for Dividend Income

The Most (Mr.) Wonderful Time of the Year for Dividend Income

The top-10 holdings of Kevin O'Leary's O'Shares FTSE U.S. Quality Dividend ETF are an interesting source of quality dividend growth stocks.

Bitten Market, Waning Volume, Virus Thoughts, Jobless Claims Quirk, CPI Watch

Bitten Market, Waning Volume, Virus Thoughts, Jobless Claims Quirk, CPI Watch

Plus, a quick look at earnings report winners and losers from Thursday after the market closed.

JNJ Move

I have eliminated my small long in at $159.49 just now.

Should Investors Believe in Bounces as Markets Get Choppy?

Should Investors Believe in Bounces as Markets Get Choppy?

Sector selection will remain paramount as pandemic effects continue to permeate.

Omicron, Black Friday, Jobs Week, Cybersecurity, Trading Zscaler

Omicron, Black Friday, Jobs Week, Cybersecurity, Trading Zscaler

I wouldn't expect a lot in the way of economic shutdowns, at least not unless clear evidence presents that people are getting sicker from Omicron.

Fingers Crossed for a Small-Cap Revenge Rally in 2022

Fingers Crossed for a Small-Cap Revenge Rally in 2022

The lingering effects of the pandemic have been hard on smaller biotech and healthcare stocks, but the worm could turn next year.

Heads Up on JNJ

A heads up. Johnson & Johnson is ex-dividend $1.06/share today.

Breaking Up - for Johnson & Johnson - Is Not Hard to Do

They say that breaking up is hard to do Now I know I know that it's true Don't say that this is the end Instead of breaking up I wish that we were making up again  - Neil Sedaka, Breaking Up Is Hard To Do   While many embrace the speculative orgy of...

New Buy (and Short) 'Levels'

* My revised levels I don't want there to be any ambiguity about the size of my positions, or about my buy and short levels, as I strive for as much transparency as possible. This column is a continued commitment towards that sort of disclosure. "Wh...

GE and JNJ Aren't the Only Aging Companies That Could Benefit From a Breakup

GE and JNJ Aren't the Only Aging Companies That Could Benefit From a Breakup

These moves could serve as a benchmark for other bigger, older, and perhaps bloated companies. Here are some candidates.

Johnson & Johnson Joins the Breakup Club: Here's How to Play It

Johnson & Johnson Joins the Breakup Club: Here's How to Play It

J&J will be separating into two distinct firms, but not right away.

AT&T Should Break Itself Up (Further)!  

This morning Johnson & Johnson joined a long and growing list, including a recently announced disaggregation, of companies that are breaking into parts.  AT&T is already disaggregating - with the Warner/Discovery deal - and perhaps should go even fu...

Are Pandemic-Driven Panic Buying Stocks Suddenly Passe?

Are Pandemic-Driven Panic Buying Stocks Suddenly Passe?

There is a lingering apprehension that the moment has passed for many of these names.

Black Monday Recollections, Bitcoin ETF Launch, Fed Numbers, FDA, Disney's Dip

Black Monday Recollections, Bitcoin ETF Launch, Fed Numbers, FDA, Disney's Dip

While cryptocurrencies are indeed an asset class, and they are divisible, they do not serve as a medium of exchange, and remain unproven as a store of value.

Here's How Johnson & Johnson Stock Looks Ahead of Earnings

Here's How Johnson & Johnson Stock Looks Ahead of Earnings

All eyes will be on JNJ as it releases its numbers Tuesday.

Super Thursday, Filling Gaps, Crypto Regulator Talk, Amazing Alcoa, AMD Love

Super Thursday, Filling Gaps, Crypto Regulator Talk, Amazing Alcoa, AMD Love

Plus, an FDA advisory panel gives a unanimous boost to a Moderna booster shot and Boeing slumps on a negative news report.

Booster Club

As you mark your October calendar for what I shared earlier, also keep your eyes on Oct. 14-15. Those are the days a panel of FDA advisors will meet to discuss whether to recommend booster shots of Covid-19 vaccines from Moderna and Johnson & Johnso...

Jim Cramer: I'll Put My Money With 'Boring but Lucrative' Any Day

Jim Cramer: I'll Put My Money With 'Boring but Lucrative' Any Day

Let's look at that recent downgrade of 'dull' Morgan Stanley and see why exciting is best left for the stadiums and amusement parks -- and not stocks.

Clinically Speaking: 6 Stocks Behind the Scenes at Drug Trials

Clinically Speaking: 6 Stocks Behind the Scenes at Drug Trials

Investors are increasingly looking to the companies involved in clinical trials. Here are six favorite names in this space.

Fed Speaks, Taper Timeline, Dot Fantasy, Evergrande, DC Circus, Booster Stocks

Fed Speaks, Taper Timeline, Dot Fantasy, Evergrande, DC Circus, Booster Stocks

It was as if markets heard what they wanted to hear, when it was actually much more simple: markets heard exactly what they had anticipated.